ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Information for professionals for Inflectra®:Pfizer PFE Switzerland GmbH
Complete information for professionalsDDDÄnderungen anzeigenPrint 
Composition.Galenic FormIndication.UsageContra IndicationWarning restrictions.Interactions.Pregnancy
Driving abilityUnwanted effectsOverdoseEffectsPharm.kinetikPreclinicalOther adviceSwissmedic-Nr.
PackagesRegistration ownerLast update of information 
L04AB02 - InfliximabATC-DDD Version 2016. Source: WHO
L - Antineoplastic and Immunomodulating Agents

This group comprises preparations used in the treatment of malignant neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.

L04 - Immunosuppressants

Immunosuppressants are defined as agents that completely or partly suppress one or more factors in the immunosystem.

L04A - Immunosuppressants

This group comprises immunosuppressants excl. corticosteroids.

The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.

L04AB - Tumor Necrosis Factor Alpha (Tnf-Α) Inhibitors
 

The DDDs for etanercept, infliximab and adalimumab are based on the treatment of rheumatoid arthritis.
The DDD for cerolizumab pegol is based on the treatment of Crohns Disease.

L04AB02 - Infliximab
DoseRoute of administrationNote
3.75 mgP 
2020 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home